KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.

Chi Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li, Wai Tong Ng, James Chung Hang Chow, Horace Cheuk Wai Choi, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Steven A Eschrich, Javier F Torres-Roca, Jason Wing Hon Wong

Radiother Oncol 196 110287

PMID38636709
PMCID-
DOI10.1016/j.radonc.2024.110287
发表日期2024-04-18
入排依据:The study is a secondary biomarker analysis (correlating GARD with locoregional control) from a randomized Phase III trial. While it meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, it does not present a primary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR from the original trial. The deterministic review correctly identified the lack of a time-to-event signal. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.
摘要

摘要

BACKGROUND: Locally advanced nasopharyngeal cancer (NPC) patients undergoing radiotherapy are at risk of treatment failure, particularly locoregional recurrence. To optimize the individual radiation dose, we hypothesize that the genomic adjusted radiation dose (GARD) can be used to correlate with locoregional control. METHODS: A total of 92 patients with American Joint Committee on Cancer / International Union Against Cancer stage III to stage IVB recruited in a randomized phase III trial were assessed (NPC-0501) (NCT00379262). Patients were treated with concurrent chemo-radiotherapy plus (neo) adjuvant chemotherapy. The primary endpoint is locoregional failure free rate (LRFFR). RESULTS: Despite the homogenous physical radiation dose prescribed (Median: 70 Gy, range 66-76 Gy), there was a wide range of GARD values (median: 50.7, range 31.1-67.8) in this cohort. In multivariable analysis, a GARD threshold (GARDT) of 45 was independently associated with LRFFR (p = 0.008). By evaluating the physical dose required to achieve the GARDT (RxRSI), three distinct clinical subgroups were identified: (1) radiosensitive tumors that RxRSI at dose < 66 Gy (N = 59, 64.1 %) (b) moderately radiosensitive tumors that RxRSI dose within the current standard of care range (66-74 Gy) (N = 20, 21.7 %), (c) radioresistant tumors that need a significant dose escalation above the current standard of care (>74 Gy) (N = 13, 14.1 %). CONCLUSION: GARD is independently associated with locoregional control in radiotherapy-treated NPC patients from a Phase 3 clinical trial. GARD may be a potential framework to personalize radiotherapy dose for NPC patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。